发布求助
文献互助 智能选刊 最新文献

Nature Reviews Clinical Oncology最新文献

筛选
英文 中文
Using oncolytic viruses to induce hyperacute rejection against cancer 利用溶瘤病毒诱导癌症超急性排斥反应
IF 82.2 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-26 DOI: 10.1038/s41571-025-01006-0
Howard L. Kaufman, Ann W. Silk
{"title":"Using oncolytic viruses to induce hyperacute rejection against cancer","authors":"Howard L. Kaufman, Ann W. Silk","doi":"10.1038/s41571-025-01006-0","DOIUrl":"10.1038/s41571-025-01006-0","url":null,"abstract":"In a recently reported study, a novel engineered oncolytic Newcastle disease virus encoding porcine α1,3-galactosyltransferase was evaluated in monkeys with CRISPR-induced primary hepatocellular carcinoma and in a phase I clinical trial. The virus induced hyperacute tumour rejection and an objective response rate of 35% in 20 evaluable patients. This approach highlights the promises and challenges of oncolytic virus drug development.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 5","pages":"309-310"},"PeriodicalIF":82.2,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The SONIA trial shows the power and challenges of academic research 索尼娅试验显示了学术研究的力量和挑战
IF 82.2 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-24 DOI: 10.1038/s41571-025-01004-2
Shani Paluch-Shimon, Fatima Cardoso
{"title":"The SONIA trial shows the power and challenges of academic research","authors":"Shani Paluch-Shimon, Fatima Cardoso","doi":"10.1038/s41571-025-01004-2","DOIUrl":"10.1038/s41571-025-01004-2","url":null,"abstract":"The thought-provoking SONIA trial showed that patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer receiving deferred (second-line) versus first-line cyclin dependent-kinase (CDK) 4/6 inhibitors have noninferior progression-free survival after second-line treatment; such an approach also results in substantial cost savings. Herein, we discuss some important limitations of this trial and argue that, owing to their effect on overall survival, CDK4/6 inhibitors should remain the standard-of-care first-line therapy.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 5","pages":"311-312"},"PeriodicalIF":82.2,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours Zenocutuzumab在NRG1融合阳性实体瘤中显示疗效
IF 82.2 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-20 DOI: 10.1038/s41571-025-01005-1
Diana Romero
{"title":"Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours","authors":"Diana Romero","doi":"10.1038/s41571-025-01005-1","DOIUrl":"10.1038/s41571-025-01005-1","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 5","pages":"308-308"},"PeriodicalIF":82.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143451475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma 经批准的cd19靶向CAR - T细胞治疗大B细胞淋巴瘤的疗效相关因素
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-18 DOI: 10.1038/s41571-025-00992-5
Tamara J. Bock, Chanukya K. Colonne, Salvatore Fiorenza, Cameron J. Turtle
{"title":"Outcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma","authors":"Tamara J. Bock, Chanukya K. Colonne, Salvatore Fiorenza, Cameron J. Turtle","doi":"10.1038/s41571-025-00992-5","DOIUrl":"10.1038/s41571-025-00992-5","url":null,"abstract":"CD19-targeted chimeric antigen receptor (CAR) T cells have provided a breakthrough in the treatment of patients with relapsed and/or refractory large B cell lymphoma (LBCL). Currently, three CD19-targeted CAR T cell products are approved by the FDA and various other regulators for the treatment of patients with LBCL: axicabtagene ciloleucel, tisagenlecleucel and lisocabtagene maraleucel. Response rates following infusion of these CD19-targeted CAR T cells have been promising; however, approximately half of treated patients show relapse within 2 years. Furthermore, receiving these agents can be associated with serious toxicities, including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. In this Review, we summarize the factors associated with the efficacy, including response and survival outcomes, and toxicity of CD19-targeted CAR T cells in pivotal clinical trials and large real-world datasets describing the outcomes of patients with LBCL who received treatment with these products. CD19-targeted CAR T cells have transformed the management of patients with relapsed and/or refractory large B cell lymphoma, and these therapies are increasingly being administered as earlier-line therapies. Nonetheless, the prognosis of these patients is often difficult to predict, with various prospective and real-world studies suggesting that a wide range of factors are associated with treatment outcomes. In this Review, the authors summarize these various associations as well as their implications for patient selection and management.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 4","pages":"241-261"},"PeriodicalIF":81.1,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143435290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Less-frequent surveillance is noninferior to annual mammography 监测频率较低的乳房 X 射线照相术并不比每年一次的乳房 X 射线照相术效果差。
IF 82.2 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-13 DOI: 10.1038/s41571-025-01001-5
Peter Sidaway
{"title":"Less-frequent surveillance is noninferior to annual mammography","authors":"Peter Sidaway","doi":"10.1038/s41571-025-01001-5","DOIUrl":"10.1038/s41571-025-01001-5","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 5","pages":"307-307"},"PeriodicalIF":82.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Artificial intelligence in digital pathology — time for a reality check 数字病理学中的人工智能——是时候进行现实检验了
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-11 DOI: 10.1038/s41571-025-00991-6
Arpit Aggarwal, Satvika Bharadwaj, Germán Corredor, Tilak Pathak, Sunil Badve, Anant Madabhushi
{"title":"Artificial intelligence in digital pathology — time for a reality check","authors":"Arpit Aggarwal, Satvika Bharadwaj, Germán Corredor, Tilak Pathak, Sunil Badve, Anant Madabhushi","doi":"10.1038/s41571-025-00991-6","DOIUrl":"10.1038/s41571-025-00991-6","url":null,"abstract":"The past decade has seen the introduction of artificial intelligence (AI)-based approaches aimed at optimizing several workflows across many medical specialties. In clinical oncology, the most promising applications include those involving image analysis, such as digital pathology. In this Perspective, we provide a comprehensive examination of the developments in AI in digital pathology between 2019 and 2024. We evaluate the current landscape from the lens of technological innovations, regulatory trends, deployment and implementation, reimbursement and commercial implications. We assess the technological advances that have driven improvements in AI, enabling more robust and scalable solutions for digital pathology. We also examine regulatory developments, in particular those affecting in-house devices and laboratory-developed tests, which are shaping the landscape of AI-based tools in digital pathology. Finally, we discuss the role of reimbursement frameworks and commercial investment in the clinical adoption of AI-based technologies. In this Perspective, we highlight both the progress and challenges in AI-driven digital pathology over the past 5 years, outlining the path forward for its adoption into routine practice in clinical oncology. The authors of this Perspective evaluate the developments in the use of artificial intelligence (AI) in digital pathology for oncology applications between 2019 and 2024, addressing technological innovations, regulatory trends, implementation and financial implications. Importantly, they explore the current landscape of clinical deployment, highlighting future opportunities for the integration of AI into clinical oncology routine practice.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 4","pages":"283-291"},"PeriodicalIF":81.1,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143393110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL 中亲和cd19导向的CAR - T细胞产品obbectagene autoeucel在R/R B-ALL中显示出良好的安全性和有效性
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-10 DOI: 10.1038/s41571-025-00993-4
Rawan G. Faramand, Frederick L. Locke
{"title":"Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL","authors":"Rawan G. Faramand, Frederick L. Locke","doi":"10.1038/s41571-025-00993-4","DOIUrl":"10.1038/s41571-025-00993-4","url":null,"abstract":"Recent data from the FELIX trial evaluating obecabtagene autoleucel in patients with relapsed and/or refractory B acute lymphoblastic leukaemia (R/R B-ALL) suggest that this novel intermediate-affinity CD19-directed chimeric antigen receptor (CAR) T cell therapy is associated with a reduced incidence of severe immune-mediated toxicities compared with other commercially available CAR T cell products. The increasing number of therapies available for B-ALL makes treatment selection and sequencing of therapies increasingly challenging.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 3","pages":"161-162"},"PeriodicalIF":81.1,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143375308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI accurately identifies targetable alterations in lung cancer histological images 人工智能可以准确识别肺癌组织学图像中的可靶向改变
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-10 DOI: 10.1038/s41571-025-00999-y
Hortense Le, Aristotelis Tsirigos
{"title":"AI accurately identifies targetable alterations in lung cancer histological images","authors":"Hortense Le, Aristotelis Tsirigos","doi":"10.1038/s41571-025-00999-y","DOIUrl":"10.1038/s41571-025-00999-y","url":null,"abstract":"DeepGEM, an artificial intelligence (AI)-based model, accurately predicts the presence of key genomic alterations in histological slides prepared from samples obtained from patients with lung cancer. This approach provides a cost-effective alternative to genomic testing, generates spatial mutation maps and might support personalized treatment strategies. Validated in diverse datasets, DeepGEM highlights the potential of AI to transform precision oncology and improve global healthcare equity.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 4","pages":"239-240"},"PeriodicalIF":81.1,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143375171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas 卡多尼利单抗对her2阴性的晚期G/GEJ腺癌有效
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-07 DOI: 10.1038/s41571-025-00998-z
Diana Romero
{"title":"Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas","authors":"Diana Romero","doi":"10.1038/s41571-025-00998-z","DOIUrl":"10.1038/s41571-025-00998-z","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 4","pages":"237-237"},"PeriodicalIF":81.1,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143367370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transanal TME noninferior to the laparoscopic approach 经肛门TME不逊于腹腔镜入路
IF 81.1 1区 医学
Nature Reviews Clinical Oncology Pub Date : 2025-02-06 DOI: 10.1038/s41571-025-00997-0
Peter Sidaway
{"title":"Transanal TME noninferior to the laparoscopic approach","authors":"Peter Sidaway","doi":"10.1038/s41571-025-00997-0","DOIUrl":"10.1038/s41571-025-00997-0","url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"22 4","pages":"237-237"},"PeriodicalIF":81.1,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143258062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信